GlassScriptPhysician profile
Lauren R Davison
NPI 1285143222
$1,556.21
in general payments reported to CMS, 2019-2025
25 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $412 · 2022: $592 · 2023: $126 · 2024: $198 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $551.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $331.99 | 2021-2025 | |
| Mylan Specialty L.P. | $264.36 | 2021-2024 | Yupelri |
| Novo Nordisk INC | $137.35 | 2021-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $100.42 | 2021-2025 | |
| Amgen INC. | $86.91 | 2021-2024 | Prolia, Evenity |
| Novartis Pharmaceuticals Corporation | $70.42 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.02 | 2021-2024 | Xifaxan |
| Lilly USA, LLC | $58.67 | 2021-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $58.01 | 2021-2023 | Vaxneuvance, M-M-R II, Gardasil 9 |
| Biohaven Pharmaceutical Holding Company LTD. | $54.96 | 2022 | |
| Viatris Specialty LLC | $45.67 | 2025 | Yupelri |
| Insulet Corporation | $39.74 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $30.05 | 2021 | |
| Glaxosmithkline, LLC. | $28.76 | 2021-2022 | |
| Astellas Pharma US INC | $28.44 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $23.92 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.82 | 2021 | |
| Amarin Pharma, INC. | $16.67 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.32 | 2023 | Austedo Xr |
| Vertex Pharmaceuticals Incorporated | $13.90 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.83 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $13.26 | 2022 | |
| Seqirus USA INC | $12.89 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.06 | 2022 | |
| Acadia Pharmaceuticals INC | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Davison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.